42 results about "Ranitidine Hydrochloride" patented technology

The invention discloses ranitidine hydrochloride capsules and a production method thereof. Every 1,000 capsules comprise 165 to 170 parts of ranitidine hydrochloride and 40 to 50 parts of calcium hydrophosphate. The preparation method for the capsules comprises the following steps: weighing the ranitidine hydrochloride and the calcium hydrophosphate according to the weight part; crushing the ranitidine hydrochloride and the calcium hydrophosphate respectively, adding 50 percent ethanol in a trough type mixing machine to mix for 20 to 40 minutes to prepare a soft material, and granulating; drying the prepared granules in a hot-air circulation drying oven at the temperature of lower than 70 DEG C, and controlling the moisture within 4 percent; and filling the dried granules in capsules, andpolishing to obtain the ranitidine hydrochloride capsules. The ranitidine hydrochloride capsules and the production method thereof have the advantages that: the calcium hydrophosphate is adopted as an auxiliary material, so that each quality index of the product in a valid period is ensured to be basically stable, the problem of hygroscopicity of the ranitidine hydrochloride capsules can be solved, the product stability is improved, and intake of talc powder and magnesium stearate is prevented.

The invention provides a ranitidine hydrochloride lipidosome capsule and new application thereof. Particularly, certain amounts of yolk lecithin, cholesterin, natrium glycocholicum, tween 80 and an active ingredient ranitidine hydrochloride are combined and are prepared into ranitidine hydrochloride lipidosome by film dispersion technology, and the ranitidine hydrochloride lipidosome is mixed with the general accessories of medicine to prepare the capsule. The ranitidine hydrochloride lipidosome capsule better solves the problems of easy deliquescence, moisture absorption, color change and poor stability of the ranitidine hydrochloride, increases preparation medical effect and biological availability and can be used for treating herpetic stomatitis of childrem.

The invention discloses a ranitidine hydrochloride releasing-controlling dry suspension and a preparing method thereof. The ranitidine hydrochloride releasing-controlling dry suspension comprises ranitidine hydrochloride and polymers which can be accepted in the pharmacy and comprises, by weight, 10%-90% of ranitidine hydrochloride, 10%-90% of auxiliary materials and the balance other auxiliary materials. The auxiliary materials with the releasing controlling effect are one or more of positive ion exchange resin, methylcellulose, ethyl cellulose, acrylic resin and hydroxypropyl methylcellulose. Compared with an immediate-release preparation, the releasing-controlling preparation can keep the effective blood concentration within 24 hours, curative effects are improved, toxic and side effects are small, taking and carrying are convenient, and the taking times are reduced. Compared with a sustained-release preparation, the releasing-controlling preparation can keep the more stable blood concentration within 24 hours, curative effects are improved, and toxic and side effects are small. According to the ranitidine hydrochloride releasing-controlling dry suspension, dosing only needs to be carried out once in one day; the releasing-controlling preparation is used for treating benign gastric ulcer and duodenal ulcer in clinic.